Literature DB >> 11408831

Diazepam stimulates migration and phagocytosis of human neutrophils: possible contribution of peripheral-type benzodiazepine receptors and intracellular calcium.

F Marino1, S Cattaneo, M Cosentino, E Rasini, L Di Grazia, A M Fietta, S Lecchini, G Frigo.   

Abstract

In isolated human neutrophils, diazepam (10 nmol/l to 10 micromol/l) concentration-dependently increased migration and phagocytosis. Diazepam-induced migration and phagocytosis were inhibited by the peripheral benzodiazepine receptor (PBR) antagonist PK11195 (10 micromol/l). The PBR agonist Ro5-4864 (10 nmol/l to 10 micromol/l) did not affect migration but slightly enhanced phagocytosis, while clonazepam, which binds to the central-type benzodiazepine receptors but has no affinity for PBRs, was ineffective on both parameters up to 10 micromol/l. Phagocytosis induced by diazepam or Ro5-4864 was inhibited by the Ca2+ channel blocker L-verapamil (10 micromol/l), which however did not affect the action of diazepam on migration. Competition binding experiments performed by fluorescent staining of PBRs showed that diazepam directly interacts with PBRs on human neutrophils. Both diazepam and Ro5-4864 (10 nmol/l to 10 micromol/l) induced a rise of intracellular free Ca2+ concentrations ([Ca2+]i), which was inhibited by PK11195 (10 micromol/l) and L-verapamil (10 micromol/l) and prevented by extracellular Ca2+ chelation with EGTA (5 mmol/l). In conclusion, experimental evidence indicates that in human neutrophils diazepam stimulates both migration and phagocytosis through activation of PBRs. Diazepam-induced [Ca2+]i changes depend on a PBR-operated, L-verapamil-sensitive increase in the plasma membrane permeability and subsequent extracellular Ca2+ entry, and contribute to diazepam-induced phagocytosis. On the contrary, the effect of diazepam on migration seems to occur through Ca2+ -independent mechanisms. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11408831     DOI: 10.1159/000056111

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  6 in total

1.  Midazolam inhibits hippocampal long-term potentiation and learning through dual central and peripheral benzodiazepine receptor activation and neurosteroidogenesis.

Authors:  Kazuhiro Tokuda; Kazuko A O'Dell; Yukitoshi Izumi; Charles F Zorumski
Journal:  J Neurosci       Date:  2010-12-15       Impact factor: 6.167

2.  Signaling mechanisms of enhanced neutrophil phagocytosis and chemotaxis by the polysaccharide purified from Ganoderma lucidum.

Authors:  Ming-Jen Hsu; Shiuh-Sheng Lee; Sho Tone Lee; Wan-Wan Lin
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

Review 3.  Translocator protein 18 kDa (TSPO): molecular sensor of brain injury and repair.

Authors:  Ming-Kai Chen; Tomás R Guilarte
Journal:  Pharmacol Ther       Date:  2008-02-09       Impact factor: 12.310

4.  Translocator protein (18 kDa) (TSPO) is expressed in reactive retinal microglia and modulates microglial inflammation and phagocytosis.

Authors:  Marcus Karlstetter; Caroline Nothdurfter; Alexander Aslanidis; Katharina Moeller; Felicitas Horn; Rebecca Scholz; Harald Neumann; Bernhard H F Weber; Rainer Rupprecht; Thomas Langmann
Journal:  J Neuroinflammation       Date:  2014-01-08       Impact factor: 8.322

5.  The Ca2+ Channel Blocker Verapamil Inhibits the In Vitro Activation and Function of T Lymphocytes: A 2022 Reappraisal.

Authors:  José Ignacio Veytia-Bucheli; Den Alejandro Alvarado-Velázquez; Lourival Domingos Possani; Roberto González-Amaro; Yvonne Rosenstein
Journal:  Pharmaceutics       Date:  2022-07-15       Impact factor: 6.525

6.  Benzodiazepine augmented γ-amino-butyric acid signaling increases mortality from pneumonia in mice.

Authors:  Robert D Sanders; Alexandra Godlee; Toshifumi Fujimori; John Goulding; Gang Xin; Samira Salek-Ardakani; Robert J Snelgrove; Daqing Ma; Mervyn Maze; Tracy Hussell
Journal:  Crit Care Med       Date:  2013-07       Impact factor: 9.296

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.